Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023

Rhea-AI Summary

Allogene Therapeutics, Inc. will report second quarter 2023 financial results on August 2, 2023. A live audio webcast and conference call will follow the announcement.

Positive

• Investors can listen to the webcast on the company's website and ask questions during the conference call.

Negative

• None.

• Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET

SOUTH SAN FRANCISCO, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report second quarter 2023 financial results on Wednesday, August 2, 2023, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 PM Pacific Time/5:00 PM Eastern Time.

Listen-Only Webcast
The listen-only webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company's website for approximately 30 days.

Conference Call Registration
If you would like the option to ask a question on the conference call, please use this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com

FAQ

When will Allogene Therapeutics report their second quarter 2023 financial results?

Allogene Therapeutics will report their second quarter 2023 financial results on August 2, 2023.

How can investors listen to the webcast?

Investors can listen to the webcast on Allogene Therapeutics' website under the Investors tab in the News and Events section.

Can investors ask questions during the conference call?

Yes, investors can ask questions during the conference call by registering through the provided link.